abstract |
The present invention relates to combination therapies for treating KRas G12C cancer. In particular, the present invention relates to the treatment of cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (IA) or Formula (IB). It relates to methods, pharmaceutical compositions comprising a therapeutically effective amount of the inhibitors, kits comprising the compositions, and methods of using the same. |